Change over period
From:
To:
Zoom:
- 1Y
- 3Y
- 5Y
- 10Y
- 15Y
- 20Y
- Max
Regencell Bioscience Holdings Ltd
NASDAQ RGC
Data sourced from
and
and
Regencell Bioscience Holdings Ltd Depreciation and Amortization 3 year CAGR for the Trailing 12 Months (TTM) ending September 30, 2023: -85.45%
Regencell Bioscience Holdings Ltd Depreciation and Amortization 3 year CAGR is -85.45% for the Trailing 12 Months (TTM) ending September 30, 2023. Depreciation and Amortization involve the systematic allocation of the cost of tangible and intangible assets over their useful lives. CAGR, or the Compound Annual Growth Rate, quantifies the mean annual growth rate of an investment or financial metric over a specified time span, considering the influence of compounding. It is instrumental in determining the true annualized return on an investment.
-
Regencell Bioscience Holdings Ltd Depreciation and Amortization for the Trailing 12 Months (TTM) ending March 31, 2022 was USD -188.77 M, a -710,658.55% change year over year.
-
Regencell Bioscience Holdings Ltd Depreciation and Amortization for the Trailing 12 Months (TTM) ending March 31, 2021 was USD 26.57 K, a -99.99% change year over year.
-
Regencell Bioscience Holdings Ltd Depreciation and Amortization for the Trailing 12 Months (TTM) ending December 31, 2017 was USD 249.70 M, a 8.24% change year over year.
-
Regencell Bioscience Holdings Ltd Depreciation and Amortization for the Trailing 12 Months (TTM) ending December 31, 2016 was USD 230.70 M.
Don’t Miss A Beat
Looking to stay ahead of the competition and stay informed? Receive your daily dose of market news, trends, and analysis to kickstart your day and stay up-to-date.
NASDAQ: RGC
| CEO | Mr. Yat-Gai Au |
| IPO Date | July 16, 2021 |
| Location | Hong Kong |
| Headquarters | First Commercial Building, Causeway Bay, Hong Kong |
| Employees | 12 |
| Sector | Healthcare |
| Industry | Drug manufacturers - specialty & generic |
Description
Regencell Bioscience Holdings Limited operates as a Traditional Chinese medicine (TCM) bioscience company in Hong Kong. It focuses on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degeneration, primarily for attention deficit hyperactivity disorder and autism spectrum disorder, as well as infectious diseases. The company was incorporated in 2014 and is headquartered in Causeway Bay, Hong Kong.
Key trends
Similar companies
Eagle Pharmaceuticals Inc
NA
NA
Phibro Animal Health Corporation
NA
NA
Procaps Group SA
NA
NA
StockViz Staff
September 20, 2024
Any question? Send us an email